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ABSTRACT
Malignant transformation of Barrett’s esophagus is characterized
by three distinct premalignant stages: intestinal metaplasia (MET),
low- (LGD), and high-grade dysplasia (HGD). We reported recently an
increase in the frequency of loss of 7q33-q35 between LGD and HGD
as determined by comparative genomic hybridization (P. H. J. Rieg-
man et al., Cancer Res., 61: 3164 –3170, 2001). Now the 7q32.3-q36.1
region was additionally characterized by allelotype analysis with 11
polymorphic markers in 15 METs, 20 LGDs, 20 HGDs, and 20 Bar-
rett’s adenocarcinomas from different patients. Low percentages of
imbalance were determined in METs and LGDs, 7% and 10%, respec-
tively, whereas HGDs and Barrett’s adenocarcinomas revealed high
percentages of loss, 75% and 65%, respectively. This difference in
frequency between LGDs and HGDs appeared highly significant:
P  0.00007. The majority of imbalances were found at D7S2439 and
D7S483, located on 7q36.1. These data suggest that markers from this
area can be used as a diagnostic tool in Barrett’s esophagus, i.e., to
distinguish between watchful waiting and active treatment.
INTRODUCTION
BE3 is replacement of the normal squamous epithelium with co-
lumnar epithelium and generally occurs in the distal part of the
esophagus, probably as a result of gastric reflux (1–3). BE is consid-
ered a precursor condition for the development of adenocarcinoma. It
includes the following stages: MET, LGD, and HGD. Over the past
decades, the incidence of BAC has increased rapidly and is most
frequently diagnosed in elderly white males (4). These adenocarcino-
mas have a very poor prognosis because of early metastatic spread and
frequent local recurrence (5). Surgery or mucosectomy is recom-
mended in patients diagnosed with HGD because of the high risk of
developing BAC (6). Therefore, it is of major importance to search for
characteristics in BE that can help to distinguish LGD from HGD.
Thus far, many genomic and protein expression aberrations have been
reported during malignant transformation in BE. However, this has
not resulted in a marker to discriminate between LGD and HGD. We
presented recently a genome-wide overview of the DNA copy number
changes during development of BAC based on comparative genomic
hybridization (7). An increase of the frequency of loss of 7q33-q35
was found between LGD and HGD, suggesting the presence of a
possible biomarker within this large genomic region. The latter study
was performed on pairs of adenocarcinomas and adjacent dysplasias
present in surgical resection specimens. Therefore, we decided to
examine the region 7q32.3-q36.1 extensively by allelotype analysis
with 11 polymorphic markers of 75 DNA samples from different
patients in successive stages of malignant progression in BE.
MATERIALS AND METHODS
Patient Material. For this study, 15 METs, 20 LGDs, and 20 HGDs were
selected from different individuals without adenocarcinoma. Histopathological
evaluation and grading of dysplasia were performed by two experienced
gastrointestinal pathologists. Abnormal and normal tissues (squamous epithe-
lium and inflammatory infiltrate) were collected from the same tissue section
and, therefore, subjected to similar experimental conditions. The 20 adenocar-
cinoma samples were taken from surgical resection specimens. The mean age
of the whole group of 75 patients was 62.5 years of age with a male:female
ratio of 6:1.
Laser Capture Microdissection and DNA Extraction. Before microdis-
secting, the 5-m formalin-fixed, paraffin-embedded sections were deparaf-
finized using standard methods, stained for 10 s with H&E, and subsequently
dehydrated and air dried. Laser capture microdissection was performed on a
Pixcell II (Arcturus, Mountain View, CA). The membrane containing the
isolated cells was carefully peeled from the cap and submerged for 2 days at
55°C in 50 l of DNA isolation buffer containing 10 mM Tris-HCl (pH 8.0),
1 mM of EDTA, 1% Tween 20, and 0.1 mg/ml proteinase K. Proteinase K was
inactivated by incubation at 95°C for 8 min.
Polymorphic Markers. Polymorphic markers were selected from the Na-
tional Center for Biotechnology Information4 and Genome Data Base5 data-
banks based on heterozygosity frequency, as well as coverage and flanking the
region of interest. The location of the primers was also compared to the draft
sequence,6 which was used in this study. The exact position of the markers is
not entirely clear, although the sequence of the markers along the chromosome
in both Genome Data Base and draft sequence databases is almost identical.
However, the position of some of the markers might change somewhat during
the finishing of the human genome sequence. New primers were designed to
shorten amplicons for markers 200 bp (Table 1), because larger amplicons
can hamper amplification on DNA isolated from formalin-fixed, paraffin-
embedded tissue. After testing, 11 markers were found suitable for additional
evaluation (Table 1).
PCR and Interpretation. The 15-l reaction mixture contained 1.5 l of
10  AmpliTaq gold buffer, 2.5 mM of MgCl2, 0.2 mM of deoxynucleotide
triphosphate, 0.9 units of AmpliTaq Gold (Perkin-Elmer, Wellesley, MA), 1 l
of DNA, 0.05 Ci [32P]dATP, and 30 ng forward and 30 ng reverse primer.
Five-minute denaturation at 95°C was followed by 35 cycles of 30 s at 95°C,
45 s at the appropriate annealing temperature (See Table 1), and 45 s at 72°C.
Elongation was achieved by 10 min at 72°C followed by chilling to 4°C. The
PCR products were mixed with 13 l of loading buffer (95% formamide, 20
mM EDTA, 0.05% bromphenol blue and 0.05% xylene cyanol), denatured for
5 min at 95°C, and kept on ice. Then 4 l of the PCR product was loaded on
a denaturing 6% polyacrylamide gel containing 7 M urea and run at 65 W for
1.5–2 h. Gels were dried and radiographed. Autoradiograms were evaluated by
visual inspection.
Allelic imbalance was defined as near or complete loss of a band in the
affected sample (MET, LGD, HGD, or BAC) relative to the corresponding
normal sample. Allelic conservation was defined as the clear presence of both
alleles in both abnormal and corresponding normal DNA. All of the other
situations were judged as noninformative.
Calculations and Statistics. The percentage of allelic imbalance in the
region 7q32.3–7q36.1 was calculated separately for METs, LGDs, HGDs, and
BACs. The Fisher’s exact test was used for statistical evaluation and compar-
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ison of percentages of aberrations. P  0.05 (two-sided) was considered the
limit of significance.
RESULTS
Allelotyping with 11 polymorphic markers covering and flanking
7q32.3-q36.1, an area of 30 Mb, was performed on 15 MET, 20
LGD, 20 HGD, and 20 BAC samples isolated by laser capture
microdissection of formalin-fixed, paraffin-embedded tissue sections
(Fig. 1). Examples of allelic imbalance are shown in Fig. 2.
Only 1 sample of the 15 tested METs showed allelic imbalance
resulting in only 7% loss, whereas 2 of 20 LGD samples revealed
allelic loss (10% imbalance). The 20 HGDs displayed 15 samples with
allelic imbalance, resulting in 75% loss. A similar percentage was
observed for the 20 BACs (13 losses; 65% allelic imbalance). A
dramatic increase in the percentage of allelic loss is seen between
LGD and HGD (Fig. 1). Comparison of the latter percentages revealed
a highly significant difference (P  0.00007).
A substantial part of the detected imbalances cover the whole area
of interest and are, therefore, not informative for defining the shortest
region of overlap. Most imbalances are found at markers D7S2439
and D7S483 (Fig. 3), located at 7q36.1. The area between D7S2439
and D7S483 showed 2 losses in 20 LGDs versus 12 losses in 20 HGDs
(Fig. 1; P  0.002).
DISCUSSION
We have confirmed and better defined the presence of a potentially
important marker for malignant progression of BE. Furthermore, we
have narrowed the area from 30 Mb, i.e., 7q33-q35 in our previous
comparative genomic hybridization study (7), to 2 Mb, i.e., the
region between markers D7S2439 and D7S483. It implies the presence
Fig. 2. Examples of allelic imbalance of the used polymorphic markers. Above every
panel the polymorphic marker name is given, whereas under the panel the corresponding
tissue is shown: L, LGD; H, HGD; T, BAC and N, normal. The patient number is depicted
at the bottom and corresponds to the numbers used in Fig. 1.
Table 1 Polymorphic markers 7q32-7q36
Amplicon Tana bp Forward 5—3 Reverse 5—3
D7S2519 57 105 CTTAGGAACTTGTGGTCCAG TGCTGTGGTGTATCCTGTGT
D7S640 60 114 TGTCTTCCAGCCCACCCC GCACATCACCAACAACGTCA
D7S500 57 154 CCAGAATTGAAAACTCAGCATT GTTCCTTAAATTAAAATGCAAGAAb
D7S509 57 141 ATAAGGACTCCTGCTATTTCTTb ACATCAAAATTCAGCACTTAAGTb
D7S684 60 157 GCACTCCAGCCTGGGTGAb GATGTTGATGTAAGACTTTCCA
D7S498c 57 141 AAAGACATGACACAAAAGGG CCATTAGATTTAGCAATATGGAA
D7S2426 57 122 GGTGGCTTGCCCAGAGC TTCCAGTGCATCTGTTTCCC
D7S636c 55 168 GAGGAGAGACTCAGAATTGGb AGCTTGTGTGGGGTTTCAG
D7S2439 57 159 CAGCAAAAGGTACAGCAATTTC GTATAACATAGGTTCATCGGCb
D7S483 57 140 TCATTAGCCTTGGCAAAATCAA TTCTCTAACCCTGTCACCAAAb
D7S2465 55 157 ACCTGGGCAACAGAGTGAG CTTCAAAGAGTTTATGCTTATGT
a Tan  Annealing temperature used in PCR reaction.
b New primers were designed to shorten amplicons for markers with amplicons larger than 200 bp, since this might hamper amplification on DNA isolated from formalin-fixed,
paraffin-embedded tissue.
c PCR was performed using 3 mM MgCl2 instead of the standard 2.5 mM concentration.
Fig. 1. Overview of allelic imbalances in different
stages of malignant progression in BE. f represent
allelic imbalance; , conservation; u, not informa-
tive. The bottom row shows the end result for all of
the tested markers, i.e., loss or conservation.
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of a possible biomarker, which, in addition, has tumor suppressive
activities. The 7q32.3-q36.1 region has not been reported frequently to
be lost in human cancers. Thus far, it has been observed in gallbladder
tumors, oral and oropharyngeal epithelial carcinomas, and leukemia
(8–10). In gallbladder tumors60% of allelic imbalance was seen for
marker D7S798. Interestingly, it is located between D7S483 and
D7S2465. We screened the critical area for known genes7 with tumor
suppressive potential and selected two possible candidates. Caspase 2
is known to stimulate apoptosis and is involved in shedding of
intestinal epithelium (11). Loss of these functions could result in
uncontrolled cell growth, which is consistent with the biological
behavior of HGD (6). However, the position of this gene, proximal in
7q35, is outside the shortest region of overlap we determined. This is
in contrast to the second candidate gene, XRCC2, which has been
reported to be located in a DNA clone together with D7S483 (12). The
latter is within our shortest region of overlap. XRCC2 is involved in
double-strand DNA repair (13). This might not only explain the
uncontrolled growth after DNA damage but could also account for the
genomic instability in BE resulting in chromosomal changes and
aneuploidy. In addition, aneuploidy has been described as a marker
for progression in BE (14). There might also be as yet undescribed
genes in this area that might turn out to be good candidates. Chro-
mosome 7 is average in gene content, and in the distal part of the q
arm some distinct gene density peaks were described (15).
It will be interesting to test the diagnostic value of the distal 7q
DNA markers, especially markers D7S2439 and D7S483 at 7q36.1, in
biopsies of BE patients, who were classified as “indefinite for dys-
plasia.” In this fashion, high-risk patients could be identified without
additional delay. A follow-up analysis of our current group was
hampered by the fact that the vast majority of patients had been
treated after a diagnosis of LGD or HGD. However, we are currently
setting up both retrospective and prospective studies to test the diag-
nostic and prognostic value of loss of distal 7q in BE patients with
MET, LGD, or indefinite for dysplasia classifications. Presently, our
biomarker could assist in the diagnosis of HGD in difficult cases.
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Fig. 3. Overview of the location of the markers and deduced imbalances observed in
7q32.3-q36.1. Locations of the 11 polymorphic markers on chromosome 7 are given by
the draft sequence (A). The deduced imbalances per sample are represented by bars along
the chromosome (B). The bars have been created by extrapolating an imbalance until a
conservation is met from another marker in the same sample, thereby considering the
noninformative markers as lost. The number of losses of each marker for all samples
(MET, LGD, HGD, and BAC) has been determined and subsequently collected in a
graphic display (C). Note the peak of loss at markers D7S2439 and D7S483.
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